RxDoctor Payments Data

Alma Leaird, MD

Rheumatology · Meridian, IDNPI 1154408219

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $856 of the $955 with a category attached, or 89.6%. 13 manufacturers reported payments, led by AbbVie at 32.2% of the total. That places this record below the midpoint for rheumatology clinicians in ID, where the typical reported total is $1,851.

$955in general payments, 2019–2025

Across 58 payments — averaging $16.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$307
  • Novartis$216
  • Johnson & Johnson$131
  • Amgen$86
  • E.r. Squibb & Sons, L.L.C.$35
  • GSK$33
  • plus $146 from 7 others

What the payments were for

  • Food & beverage$85690%
  • Education$9910%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$955 in reported general payments places this provider in the 40th percentile of 28 rheumatology providers in Idaho.

See all rheumatology providers in Idaho

Medicare billing

Part B allowed, 2024
$8,340
Medicare patients
41
Services billed
76

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab128$959,527
Enbrel SureclickEtanercept36$260,791
Enbrel MiniEtanercept25$165,307
Xeljanz XrTofacitinib Citrate19$108,397
ActemraTocilizumab22$86,369
Orencia ClickjectAbatacept13$71,389
OtezlaApremilast15$70,320
Actemra ActpenTocilizumab11$51,803
Celecoxib155$6,405
Hydroxychloroquine Sulfate162$4,488
MethotrexateMethotrexate Sodium200$2,741
Febuxostat13$2,552
Prednisone232$1,608
Mycophenolate Mofetil25$1,403
Methylprednisolone86$1,373

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$86$70,32015 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 28 rheumatology providers in Idaho.

Other rheumatology in Meridian

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →